Effect of Zinc sulfate in Diabetic Hemodialysis patients

Phase 3

• Conditions: N18.6; End stage renal disease; Diabetic Hemodialysis.

• Registration Number: IRCT20191217045765N1
• Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Diabetic Hemodialysis patients
Age:15-70 years old
Pass at least 6 months from hemodialysis
Not having inflammatory diseases affecting on serum inflammatory markers
Not consuming supplements containing antioxidants, Zinc supplement, vitamins E and C supplements and Steroidal and Non-Steroidal Anti-Inflammatory drugs(NSAIDs) one month before the start of the study

Exclusion Criteria

Consumption of antibiotics or existence of infectious and feverish illnesses one month before starting the study
Existence of diseases affecting serum galectin-3 such as cardiovascular disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum galectin-3. Timepoint: Before and after 8-week intervention. Method of measurement: It measured by ELISA method with standard kit.